ProEncia Biotechnology, a biopharma startup based in the Twin Cities, has announced the completion of pre-seed financing to support development of its periodontal disease treatment platform. According to the company, the funding will be used to continue development of a pipeline of non-invasive periodontal care products intended for patients with periodontal disease across different stages of severity.
“According to the World Health Organization, more than one billion people globally, and more than 100 million people in the US, suffer from periodontal disease,” said Tapos Ghosh, CEO and Co-Founder, ProEncia Biotechnology. “There’s an urgent need for innovation to resolve this epidemic and bring safe, effective solutions to lifelong sufferers of this condition.”
The company also stated that it has received confirmation from the United States Patent and Trademark Office regarding its provisional patent application (No. 63/765,225), titled “Compositions and Method for Prophylactic, Symptomatic, Therapeutic, and Cosmetic Periodontal Care.” ProEncia said this application is now incorporated into a non-provisional PCT International application (No. 19/548,447) and has entered the federal patent filing system.
“The commercial demand for a new approach to periodontal treatment is enormous,” said Austin Loeb, COO and Co-Founder, ProEncia Biotechnology. “The ProEncia team is committed to advancing its groundbreaking treatment and expanding care options for periodontal disease patients.”
For dental professionals, the announcement signals continued early-stage activity in the development of non-invasive therapeutic approaches for periodontal care, as well as ongoing intellectual property efforts related to prophylactic, symptomatic, therapeutic, and cosmetic applications.
Additional information is available at www.proenciabio.com.
